查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1476425

骨关节炎治疗的全球市场预测（-2030）：按治疗方法、解剖学、给药途径、分销管道和区域进行分析

Osteoarthritis Therapeutics Market Forecasts to 2030 - Global Analysis By Treatment, Anatomy, Route of Administration, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

2023年，全球骨关节炎治疗市场规模为96亿美元，预计在预测期内复合年增长率为9.7%，到2030年将达到184亿美元。骨关节炎治疗的目的在于控制疼痛、改善关节功能并减缓疾病进展。

非药物介入包括运动、体重管理和物理治疗。药物选择包括止痛药，如对乙酰胺酚和非类固醇抗发炎药物来缓解疼痛，关节内注射皮质类固醇和透明质酸可以缓解症状。也使用葡萄糖胺和硫酸软骨素等缓解疾病的药物，但其有效性存在争议。在严重的情况下，也可以考虑手术干预，例如关节重建。

根据《柳叶刀》杂誌 2023 年 9 月发表的一项研究，2020 年全球有 5.95 亿人患有骨关节炎，亚太地区的盛行率为每 10 万人中 8,632.7 人。如此高的数字表明该地区对治疗药物的需求不断增加。

对疼痛管理的需求不断增长

随着越来越多的人寻求骨关节炎疼痛的解决方案，对骨关节炎治疗的整体需求也在增加。这意味着随着越来越多的患者需要这些治疗，市场将会扩大，提供这些治疗的製药公司和医疗保健提供者的收益增加，以及骨关节炎特异性止痛药物的开发，这将导致行销的开展。这包括非类固醇抗发炎药和止痛药等口服药物、乳霜和凝胶等外用药物以及皮质类固醇和透明质酸等注射药物，以增强疼痛管理并进一步促进市场成长。

药物副作用

骨关节炎治疗会带来令人不快或严重的副作用，这可能会使患者不太可能按处方服用药物。结果，疼痛和发炎可能变得不受控制，可能使病情恶化并增加医疗费用。您也可能会出现需要进一步治疗的併发症，例如非类固醇抗发炎药物引起的胃溃疡。这给医疗保健系统和个人预算带来了压力。药物使用的不一致也会降低治疗效果并阻碍整体市场表现。

骨关节炎盛行率上升

随着越来越多的人被诊断出患有骨关节炎，对治疗的需求自然会增加，有助于在早期阶段控制骨关节炎，并在后期需要强化药物治疗或关节关节重建，以减缓或预防疾病的治疗方法正在引起人们的注意。这将为提供骨关节炎治疗的製药公司和医疗保健提供者带来不断成长的市场。

疾病改善有限

由于不能改变病程，重复患者较多。随着骨关节炎的恶化，患者可能需要使用相同或逐渐更强的药物进行持续的治疗方法，也可能导致患者对现有治疗方法的不满。患者可能会觉得他们的症状没有有效解决，因为儘管使用药物，疼痛和关节恶化仍然持续。这给患者和医疗保健系统造成了重复成本的循环，阻碍了市场成长。

COVID-19 的影响

远端医疗和远端监控已成为人们关注的焦点，并影响了处方模式。对缓解症状的需求仍在继续，但经济不确定性可能影响了负担能力和获得治疗的机会。儘管研发面临挑战，但也存在创新机会，特别是在远端病患管理和虚拟临床试验方面。总体而言，COVID-19 凸显了适应性、以患者为中心的方法和适应力在骨关节炎治疗市场动态中的重要性。

关节关节内粘稠补充疗法预计在预测期内将是最大的

由于关节内粘稠补充疗法提供了一种替代治疗选择，预计该细分市场将出现良好的增长，特别是对于其他传统疗法（如非类固醇消炎剂和皮质类固醇注射）没有反应的 OA 患者。这些药物使骨关节炎患者的治疗选择多样化。这使得医生能够根据患者的个别需求和偏好制定治疗计划，从而采用更个人化的疾病管理方法。

预计膝骨关节炎领域在预测期内复合年增长率最高

膝骨关节炎是膝骨关节炎最常见的形式之一，导致对缓解疼痛、减少发炎和改善关节功能的治疗药物的大量需求，预计该领域将以最高的复合年增长率增长。这种高需求正在推动製药公司的研发工作，以创新和改进现有治疗方法，并开发专门针对膝骨关节炎的新治疗方法。

比最大的地区

由于医疗保健支出增加、人口增长、医疗进步、监管支持和意识增强，预计亚太地区将在预测期内占据最大的市场占有率。在中国、日本和印度等国家人口老化和治疗创新的推动下，亚太地区预计将显着成长。製药公司正在投资产品开发的合作研究，有利的监管环境正在推动对症状和疾病缓解疗法的需求。

复合年增长率最高的地区：

由于肥胖率高和政府支持政策等多种因素，预计北美在预测期内将呈现最高的复合年增长率。诺华 (Novartis AG)、辉瑞 (Pfizer)、Zimmer Biomet 和葛兰素史克 (GlaxoSmithKline plc) 等主要市场参与者正在进一步巩固其地位。製药巨头之间的治疗研究试验、合併、收购和联盟等策略性倡议正在积极塑造竞争格​​局。例如，2024年2月，诺华宣布进一步继续一项生物干预研究，检视膝骨关节炎患者关节内注射卡那奴单抗和LNA043的安全性、耐受性和有效性。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场公司的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球骨关节炎治疗市场：依治疗方法

  • 关节内粘稠补充疗法剂
  • 皮质类固醇
  • 玻尿酸注射
  • 非类固醇消炎剂(NSAID)
    • 萘普生
    • 双氯芬酸钠
    • 阿斯匹灵
    • Ibuprofen
  • 止痛药
    • 乙酰胺酚
    • Duloxetine
  • 其他治疗方法

第六章全球骨关节炎治疗市场：解剖结构

  • 髋骨关节炎
  • 手骨关节炎
  • 小关节骨关节炎
  • 膝骨关节炎
  • 踝骨关节炎
  • 其他解剖结构

第七章全球骨关节炎治疗市场：依给药途径

  • 肠外给药
  • 局部给药
  • 口服给药
  • 其他给药途径

第八章全球骨关节炎治疗市场：按分销管道

  • 医院药房
  • 零售药房
  • 药局
  • 电子商务

第九章全球骨关节炎治疗市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东/非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司概况

  • GlaxoSmithKline plc
  • Sanofi SA
  • Bayer AG
  • Pfizer Inc
  • Novartis AG
  • Zimmer Biomet
  • Assertio Therapeutics, INC.
  • Anika Therapeutics
  • Bioventus
  • Ferring Pharmaceuticals Inc.
  • Abbvie Inc.
  • Amgen Inc.
  • Boehringer Ingelheim International GmbH.
  • Samsung Bioepis.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals Industries Ltd.
  • AstraZeneca PLC
  • Stryker Corporation
  • Merck & Co Inc.
Product Code: SMRC25971

According to Stratistics MRC, the Global Osteoarthritis Therapeutics Market is accounted for $9.6 billion in 2023 and is expected to reach $18.4 billion by 2030 growing at a CAGR of 9.7% during the forecast period. Osteoarthritis therapeutics aim to manage pain, improve joint function, and slow disease progression. Non-pharmacological interventions include exercise, weight management, and physical therapy. Pharmacological options encompass analgesics like acetaminophen and NSAIDs for pain relief, while intra-articular injections of corticosteroids or hyaluronic acid may alleviate symptoms. Disease-modifying drugs such as glucosamine and chondroitin sulfate are also utilized, albeit their efficacy is debated. Surgical interventions like joint replacement surgery are considered in severe cases.

According to a study published by The Lancet in September 2023, globally, 595 million people had osteoarthritis in 2020, with the Asia Pacific region accounting for a prevalence of 8632.7 per 100,000. Such high figures indicate an increasing demand for therapeutics in the region.

Market Dynamics:

Driver:

Growing demand for pain management

As more people seek solutions for osteoarthritis pain, the overall demand for osteoarthritis therapeutics rises. This translates to a larger market with more patients requiring treatment, leading to increased revenue for pharmaceutical companies and healthcare providers offering these therapies and development and marketing of pain-relieving medications specifically designed for osteoarthritis. This includes oral medications like NSAIDs and analgesics, topical applications like creams and gels, and injectable options like corticosteroids and hyaluronic acid enhancing the pain management and further boosting the market growth.

Restraint:

Adverse side effects of medications

Osteoarthritis medications come with unpleasant or even serious side effects, patients might be less likely to take them as prescribed. This can lead to uncontrolled pain, inflammation, and potentially a worsening of the condition and can lead to additional healthcare costs. Patients might experience complications requiring further treatment, such as stomach ulcers from NSAIDs. This puts a strain on healthcare systems and individual budgets. Thus inconsistency in medication use also reduces the effectiveness of the treatment, hindering the overall market performance.

Opportunity:

Rising prevalence of osteoarthritis

As more and more people are diagnosed with osteoarthritis, the demand for treatments naturally increases and focuses on treatments that can help manage osteoarthritis in its early stages, potentially delaying or preventing the need for stronger medications or joint replacements later. This translates to a larger market for pharmaceutical companies and healthcare providers offering osteoarthritis therapeutics.

Threat:

Limited disease modification

The inability to modify the disease course often leads to repeat customers. Patients may require ongoing treatment regimens with the same or progressively stronger medications as their osteoarthritis worsens and can also lead to patient dissatisfaction with available treatments. Patients might feel their condition is not being effectively addressed, as they experience ongoing pain and joint deterioration despite medication use. This creates a cycle of recurring costs for patients and healthcare systems hampering the market growth.

Covid-19 Impact

Telemedicine and remote monitoring gained prominence, influencing prescribing patterns. While demand for symptomatic relief persisted, economic uncertainties may have affected affordability and access to treatments. Research and development efforts faced challenges, but also opportunities for innovation, particularly in remote patient management and virtual clinical trials. Overall, COVID-19 underscored the importance of adaptability, patient-centric approaches, and resilience in navigating market dynamics for osteoarthritis therapeutics.

The viscosupplementation agents segment is expected to be the largest during the forecast period

The viscosupplementation agents segment is estimated to have a lucrative growth, as these agents provide an alternative treatment option for OA patients, especially those who do not respond well to other conventional therapies like NSAIDs or corticosteroid injections. These agents have diversified the treatment options available for osteoarthritis patients. This has led to a more personalized approach to managing the condition, as physicians can now tailor treatment plans based on individual patient needs and preferences.

The knee osteoarthritis segment is expected to have the highest CAGR during the forecast period

The knee osteoarthritis segment is anticipated to witness the highest CAGR growth during the forecast period, because knee osteoarthritis is one of the most common forms of OA, leading to a substantial demand for therapeutics targeting pain relief, inflammation reduction, and improvement in joint function. This high demand drives research and development efforts by pharmaceutical companies to innovate and improve existing treatments or develop new ones specifically tailored for knee osteoarthritis.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the increased healthcare spending, population growth, medical advancements, regulatory support, and improved awareness. It's projected to experience significant growth, driven by aging populations and treatment innovation in countries such as China, Japan, and India. Pharmaceutical firms are investing in research collaborations for product development, and a favorable regulatory scenario, driving demand for both symptomatic relief and disease-modifying treatments.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, due to various factors, including the region's high prevalence of obesity and supportive government policies. Key market players such as Novartis AG, Pfizer, Zimmer Biomet, and GlaxoSmithKline plc further solidify its position. Strategic initiatives such as therapeutics study trials, mergers, acquisitions, and partnerships among pharmaceutical giants are actively shaping the competitive landscape. For instance, in February 2024, Novartis announced further continuation of its study for biological interventions U.S., which are safety, tolerability and efficacy of intra-articular Canakinumab and LNA043 for patients with knee osteoarthritis

Key players in the market

Some of the key players in the Osteoarthritis Therapeutics Market include GlaxoSmithKline plc, Sanofi SA, Bayer AG, Pfizer Inc, Novartis AG, Zimmer Biomet, Assertio Therapeutics, INC., Anika Therapeutics, Bioventus, Ferring Pharmaceuticals Inc., Abbvie Inc., Amgen Inc., Boehringer Ingelheim International GmbH., Samsung Bioepis., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., AstraZeneca PLC, Stryker Corporation and Merck & Co Inc.

Key Developments:

In April 2024, Novartis implements manufacturing adjustments for ribociclib to ensure alignment with latest regulatory standards in eBC by end of Q2. This does not impact patient use or commercial supply of Kisqali(R) in its approved indication of metastatic breast cancer (mBC).

In March 2024, ViiV Healthcare announces interim data at CROI indicating superior efficacy of long-acting injectable HIV treatment Cabenuva (cabotegravir + rilpivirine) compared to daily oral therapy in individuals living with HIV who have adherence challenges.

In February 2024, GSK plc announced that it has completed the acquisition of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions.

Treatments Covered:

  • Viscosupplementation Agents
  • Corticosteroids
  • Hyaluronic Acid Injection
  • Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  • Analgesics
  • Other Treatments

Anatomies Covered:

  • Hip Osteoarthritis
  • Hand Osteoarthritis
  • Small-Joint Osteoarthritis
  • Knee Osteoarthritis
  • Ankle Osteoarthritis
  • Other Anatomies

Route of Administrations Covered:

  • Parenteral Route
  • Topical Route
  • Oral Route
  • Other Route of Administrations

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • E-Commerce

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Osteoarthritis Therapeutics Market, By Treatment

  • 5.1 Introduction
  • 5.2 Viscosupplementation Agents
  • 5.3 Corticosteroids
  • 5.4 Hyaluronic Acid Injection
  • 5.5 Non-steroidal Anti-inflammatory Drugs (NSAIDs)
    • 5.5.1 Naproxen
    • 5.5.2 Diclofenac
    • 5.5.3 Aspirin
    • 5.5.4 Ibuprofen
  • 5.6 Analgesics
    • 5.6.1 Acetaminophen
    • 5.6.2 Duloxetine
  • 5.7 Other Treatments

6 Global Osteoarthritis Therapeutics Market, By Anatomy

  • 6.1 Introduction
  • 6.2 Hip Osteoarthritis
  • 6.3 Hand Osteoarthritis
  • 6.4 Small-Joint Osteoarthritis
  • 6.5 Knee Osteoarthritis
  • 6.6 Ankle Osteoarthritis
  • 6.7 Other Anatomies

7 Global Osteoarthritis Therapeutics Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Parenteral Route
  • 7.3 Topical Route
  • 7.4 Oral Route
  • 7.5 Other Route of Administrations

8 Global Osteoarthritis Therapeutics Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Drug Stores
  • 8.5 E-Commerce

9 Global Osteoarthritis Therapeutics Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 GlaxoSmithKline plc
  • 11.2 Sanofi SA
  • 11.3 Bayer AG
  • 11.4 Pfizer Inc
  • 11.5 Novartis AG
  • 11.6 Zimmer Biomet
  • 11.7 Assertio Therapeutics, INC.
  • 11.8 Anika Therapeutics
  • 11.9 Bioventus
  • 11.10 Ferring Pharmaceuticals Inc.
  • 11.11 Abbvie Inc.
  • 11.12 Amgen Inc.
  • 11.13 Boehringer Ingelheim International GmbH.
  • 11.14 Samsung Bioepis.
  • 11.15 Sun Pharmaceutical Industries Ltd.
  • 11.16 Teva Pharmaceuticals Industries Ltd.
  • 11.17 AstraZeneca PLC
  • 11.18 Stryker Corporation
  • 11.19 Merck & Co Inc.

List of Tables

  • Table 1 Global Osteoarthritis Therapeutics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Osteoarthritis Therapeutics Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 3 Global Osteoarthritis Therapeutics Market Outlook, By Viscosupplementation Agents (2021-2030) ($MN)
  • Table 4 Global Osteoarthritis Therapeutics Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 5 Global Osteoarthritis Therapeutics Market Outlook, By Hyaluronic Acid Injection (2021-2030) ($MN)
  • Table 6 Global Osteoarthritis Therapeutics Market Outlook, By Non-steroidal Anti-inflammatory Drugs (NSAIDs) (2021-2030) ($MN)
  • Table 7 Global Osteoarthritis Therapeutics Market Outlook, By Naproxen (2021-2030) ($MN)
  • Table 8 Global Osteoarthritis Therapeutics Market Outlook, By Diclofenac (2021-2030) ($MN)
  • Table 9 Global Osteoarthritis Therapeutics Market Outlook, By Aspirin (2021-2030) ($MN)
  • Table 10 Global Osteoarthritis Therapeutics Market Outlook, By Ibuprofen (2021-2030) ($MN)
  • Table 11 Global Osteoarthritis Therapeutics Market Outlook, By Analgesics (2021-2030) ($MN)
  • Table 12 Global Osteoarthritis Therapeutics Market Outlook, By Acetaminophen (2021-2030) ($MN)
  • Table 13 Global Osteoarthritis Therapeutics Market Outlook, By Duloxetine (2021-2030) ($MN)
  • Table 14 Global Osteoarthritis Therapeutics Market Outlook, By Other Treatments (2021-2030) ($MN)
  • Table 15 Global Osteoarthritis Therapeutics Market Outlook, By Anatomy (2021-2030) ($MN)
  • Table 16 Global Osteoarthritis Therapeutics Market Outlook, By Hip Osteoarthritis (2021-2030) ($MN)
  • Table 17 Global Osteoarthritis Therapeutics Market Outlook, By Hand Osteoarthritis (2021-2030) ($MN)
  • Table 18 Global Osteoarthritis Therapeutics Market Outlook, By Small-Joint Osteoarthritis (2021-2030) ($MN)
  • Table 19 Global Osteoarthritis Therapeutics Market Outlook, By Knee Osteoarthritis (2021-2030) ($MN)
  • Table 20 Global Osteoarthritis Therapeutics Market Outlook, By Ankle Osteoarthritis (2021-2030) ($MN)
  • Table 21 Global Osteoarthritis Therapeutics Market Outlook, By Other Anatomies (2021-2030) ($MN)
  • Table 22 Global Osteoarthritis Therapeutics Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 23 Global Osteoarthritis Therapeutics Market Outlook, By Parenteral Route (2021-2030) ($MN)
  • Table 24 Global Osteoarthritis Therapeutics Market Outlook, By Topical Route (2021-2030) ($MN)
  • Table 25 Global Osteoarthritis Therapeutics Market Outlook, By Oral Route (2021-2030) ($MN)
  • Table 26 Global Osteoarthritis Therapeutics Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 27 Global Osteoarthritis Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 28 Global Osteoarthritis Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 29 Global Osteoarthritis Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 30 Global Osteoarthritis Therapeutics Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 31 Global Osteoarthritis Therapeutics Market Outlook, By E-Commerce (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.